Intech Investment Management LLC Purchases New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Intech Investment Management LLC acquired a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF) during the fourth quarter, HoldingsChannel reports. The fund acquired 18,266 shares of the company’s stock, valued at approximately $79,000.

Other large investors also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of Cardiff Oncology during the fourth quarter worth $56,000. Glenview Trust co acquired a new stake in Cardiff Oncology in the fourth quarter worth about $104,000. HB Wealth Management LLC bought a new stake in Cardiff Oncology during the 4th quarter worth about $105,000. Barclays PLC lifted its position in Cardiff Oncology by 291.9% during the 3rd quarter. Barclays PLC now owns 53,089 shares of the company’s stock valued at $141,000 after purchasing an additional 39,542 shares during the period. Finally, HighTower Advisors LLC boosted its stake in shares of Cardiff Oncology by 123.1% in the 4th quarter. HighTower Advisors LLC now owns 34,213 shares of the company’s stock valued at $148,000 after purchasing an additional 18,880 shares during the last quarter. Institutional investors own 16.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. HC Wainwright lifted their target price on shares of Cardiff Oncology from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Piper Sandler lifted their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th.

Cardiff Oncology Price Performance

Cardiff Oncology stock opened at $3.29 on Friday. Cardiff Oncology, Inc. has a fifty-two week low of $2.01 and a fifty-two week high of $6.38. The firm has a market capitalization of $218.86 million, a price-to-earnings ratio of -3.50 and a beta of 1.73. The company’s 50 day simple moving average is $3.99 and its 200 day simple moving average is $3.44.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.